Clinical trial to investigate the efficacy of Spironolactone compared with placebo in patients with acute retinal edema

Study of sprinolactone effect as a treatment for Acute Central Serous Chorio-Retinopathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016051627882N1

Enrollment

Registered

2016-12-12

Start date

2015-08-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Central Serous Chorio-Retinopathy (CSCR). Chorioretinal Inflammation H30.0 Focal chorioretinal inflammation Focal: chorioretinitis choroiditis retinitis retinochoroiditis

Interventions

Intervention 1: Intervention group: Upon diagnosis of CSR, patients will undergo treatment with 25 mg spironolactone, produced by Minoo Pharmaceutical Company, for four weeks. Patients will be monitor

Treatment - Drugs

Placebo

Intervention group: Upon diagnosis of CSR, patients will undergo treatment with 25 mg spironolactone, produced by Minoo Pharmaceutical Company, for four weeks. Patients will be monitored by the resear

Control group: Patients in this group will undergo placebo treatment taking one tablet a day for at least one month. Placebo will consist of distilled water and starch in 100 milligrams, with no side

Eligibility

Sex/Gender

All

Age

19 Years to 49 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients suffering from CSCR in its acute phase (duration of the disease being less than a month). Exclusion criteria : Patients with history of corticosteroids use; CSCR receiving treatment; other eye diseases such as corneal scar, cataract, retinopathy, and etc; multiple and recurring CSSR; pregnancy; heart disease; kidney disease and hypertension

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The volume of fluid under the retina and macular thickness. Timepoint: Upon entry, two weeks later, a month later. Method of measurement: OCT.;Visual acuity. Timepoint: Upon entry, two weeks later, a month later. Method of measurement: Snellen chart.	—

Secondary

Measure	Time frame
Drug adverse effect. Timepoint: Upon entry, two weeks later, a month later. Method of measurement: According to patient's statement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMr Mohammad Mohsen Keshmirshekan

Shahid Sadoughi University of Medical Science

dr.mkeshmirshekan@yahoo.com; nooshin.yoshany@gmail.com; mkeshmirshekan@ssu.ac.ir

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026